Form 4: Zimmer Biomet Director Boosts Deferred Stock Holdings

Zimmer Biomet Holdings, Inc. Director Devdatt Kurdikar increased his beneficial ownership of phantom stock units through the company's deferred compensation plan.

Summary

• Devdatt Kurdikar, a Director at Zimmer Biomet Holdings, Inc. (ZBH), acquired 140.163 phantom stock units.
• The transaction occurred on September 30, 2025.
• These units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
• Following this transaction, Kurdikar beneficially owns a total of 1,613.887 phantom stock units.
• The phantom stock units are convertible on a 1-for-1 basis into shares of common stock.
• The conversion or exercise price of the derivative security is $98.1.
• The total beneficial ownership includes 3.428 phantom stock units accrued on July 31, 2025, via dividend reinvestment.

Sentiment

Score: 6

Explanation: Slightly positive as a director is increasing their beneficial stake, even if through a deferred compensation plan, indicating continued alignment with the company's future performance.

Positives

• Director Devdatt Kurdikar increased his beneficial ownership in the company, potentially signaling confidence in the company's future prospects.
• The increase is part of a structured deferred compensation plan, which aligns director interests with long-term shareholder value.

Future Outlook

The phantom stock units are scheduled to be settled in shares of Zimmer Biomet Holdings, Inc. common stock within sixty days after the reporting person ceases service as a Director.

Industry Context

This transaction reflects a standard practice in executive and director compensation within the medical device industry, where equity-based awards, including deferred compensation plans, are used to align leadership interests with long-term company performance and shareholder returns.

Comparison to Industry Standards

• N/A. This filing reports an individual insider transaction and does not provide data for direct comparison to industry-wide benchmarks or specific competitor projects/results.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the director's increased equity stake as a positive signal of confidence in the company's future and long-term strategy.

Next Steps

• Settlement of phantom stock units into common stock within 60 days after Devdatt Kurdikar ceases service as a Director.

Key Dates

Keywords

Zimmer Biomet, ZBH, Devdatt Kurdikar, Insider Transaction, Form 4, Phantom Stock Units, Deferred Compensation, Director Compensation, Equity Compensation, Medical Devices